Regular Article
Tamoxifen in Platinum-Refractory Ovarian Cancer: A Gynecologic Oncology Group Ancillary Report,☆☆,

https://doi.org/10.1006/gyno.1996.0181Get rights and content
Under a Creative Commons license
open archive

Abstract

There is a critical need to find additional effective therapies in the management of ovarian cancer. A previously reported Gynecologic Oncology Group trial demonstrated that tamoxifen is an active drug when used in the salvage setting in this malignancy. Unfortunately, this original report did not specifically examine the utility of tamoxifen in patients with clinically defined platinum-refractory disease. In this reanalysis of the results of treatment of 102 evaluable patients entered into this multi-institutional trial, an objective response rate of 13% (95% confidence interval, 6.4–22.6%) was observed in patients with cisplatin-refractory ovarian cancer. The median response duration in this patient population was 4.4 months (range 1.2–9.2 months). Although the response rate is modest, this well-tolerated hormonal agent is a reasonable therapeutic option in selected patients with ovarian cancer when salvage therapy is to be considered. A possible role for this hormonal agent in other clinical settings in ovarian cancer will need to be defined through the conduct of carefully designed randomized clinical trials.

Cited by (0)

Address reprint requests to GOG Administrative Office, Suite 1945, 1234 Market Street, Philadelphia, PA 19107.

☆☆

This study was supported by National Cancer Institute grants of the Gynecologic Oncology Group Administrative Office (CA 27469) and the Gynecologic Oncology Group Statistical Office (CA 37517).

The following Gynecologic Oncology Group institutions participated in this study: University of Alabama at Birmingham, The Oregon Health Sciences Center University, Duke University Medical Center, Temple University Health Science Center Hospital, University of Rochester Medical Center, Walter Reed Army Medical Center, University of Minnesota Medical School, Colorado Foundation for Medical Care, University of California Medical Center at Los Angeles, University of Miami School of Medicine, Georgetown University Hospital, University of Iowa Hospitals and Clinics, Indiana University Medical Center, Bowman Gray School of Medicine of Wake Forest University, The Albany Medical College of Union University, University of California Medical Center at Irvine, Illinois Cancer Council, University of Pittsburgh School of Medicine, St. Louis University Medical Center, Jacksonville University Hospital, Latter Day Saints Hospital, Eastern Virginia Medical School, University of New Mexico Cancer Research and Treatment Center, Cleveland Clinic Foundation, State University of New York at Stony Brook, and Pennsylvania Hospital.